PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes
Summary
Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk randomized trial, presented at the #TCT23 Congress.
The analysis reveals comparable outcomes for TAVI and SAVR, with nuanced differences favouring each approach. Prof. Leon emphasizes the importance of long-term data and advancing technology for deeper insights in the future. They also highlight the ongoing need for further investigation, particularly in younger patients. Finally, Prof. Leon shares his mentoring experience, offering valuable suggestions for fellows involved in structural intervention research and practice.
